Liquid Biopsy - Global Market Outlook (2017-2023)

November 2017 | 152 pages | ID: LCF405465DCEN
Stratistics Market Research Consulting

Abstracts

According to Stratistics MRC, the Global Liquid Biopsy market is expected to grow from $310.0 million in 2016 to reach $1201.52 million by 2023 with a CAGR of 21.3%. Increasing research & developments and clinical trials for diagnostics, and technological developments are some of the factors driving the market growth. Moreover, growing prevalence of cancer, increasing awareness about liquid biopsy are the factors fostering the market growth. On the other hand, higher costs and complex regulations are restraining the market growth.

Liquid biopsy tests are used to help find cancer at an early stage. These tests are performed to interpret the molecular aspects of cancer across the healthcare and research settings, such as research laboratories, physicians, pathological and hospitals. The circulating tumor cells leads the market globally with the largest market share and is expected to grow with a highest CAGR during the forecast period. By cancer type, lung cancer segment is expected to witness high growth rate during the forecast period. North America emerged as the major revenue generating region in the global market due to innovative technological developments, and increasing incidence of cancer rates in the Canada and U.S.

Some of the key players in global liquid biopsy market include Roche Diagnostics, Guardant Health, Inc, Illumina, Inc, Biocept, Inc, Myriad Genetics, Inc, Qiagen N.V., Genomic Health, Inc

Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Inc, Epic Sciences, Exosome, Cynvenio Guardant Health, Personal Genome Diagnostics and Janssen Diagnostics, LLC.

Clinical Applications Covered:

• Treatment Monitoring
• Recurrence Monitoring
• Early Cancer Screening
• Therapy Selection

Product and Services Covered:

• Platforms & Instruments
• Assay Kits & Reagents
• Services

Cancer Types Covered:

• Breast Cancer
• Liver Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Other Cancer Types

Circulating Biomarkers Covered:

• Circulating Tumor DNA (CTDNA)
• Extracellular Vesicles (Evs)
• Circulating Tumor Cells
• Cell-Free DNA
• Exosomes
• Other Circulating Biomarkers

Sample Types Covered:

• Urine
• Blood
• Other Sample Types

End Users Covered:

• Academic and Research Centers
• Hospitals and Physician Laboratories
• Diagnostic centres & Reference Laboratories

Regions Covered:

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• UK
• Italy
• France
• Spain
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Australia
• New Zealand
• South Korea
• Rest of Asia Pacific
• South America
• Argentina
• Brazil
• Chile
• Rest of South America
• Middle East & Africa
• Saudi Arabia
• UAE
• Qatar
• South Africa
• Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country level segments
• Market share analysis of the top industry players
• Strategic recommendations for the new entrants
• Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
  2.4.1 Data Mining
  2.4.2 Data Analysis
  2.4.3 Data Validation
  2.4.4 Research Approach
2.5 Research Sources
  2.5.1 Primary Research Sources
  2.5.2 Secondary Research Sources
  2.5.3 Assumptions

3 MARKET TREND ANALYSIS

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Application Analysis
3.8 Emerging Markets
3.9 Futuristic Market Scenario

4 PORTERS FIVE FORCE ANALYSIS

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION

5.1 Introduction
5.2 Treatment Monitoring
5.3 Recurrence Monitoring
5.4 Early Cancer Screening
5.5 Therapy Selection

6 GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT AND SERVICE

6.1 Introduction
6.2 Platforms & Instruments
6.3 Assay Kits & Reagents
6.4 Services

7 GLOBAL LIQUID BIOPSY MARKET, BY CANCER TYPE

7.1 Introduction
7.2 Breast Cancer
7.3 Liver Cancer
7.4 Lung Cancer
7.5 Colorectal Cancer
7.6 Prostate Cancer
7.7 Other Cancer Types

8 GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER

8.1 Introduction
8.2 Circulating Tumor DNA (CTDNA)
8.3 Extracellular Vesicles (Evs)
8.4 Circulating Tumor Cells
8.5 Cell-Free DNA
8.6 Exosomes
8.7 Other Circulating Biomarkers

9 GLOBAL LIQUID BIOPSY MARKET, BY SAMPLE TYPE

9.1 Introduction
9.2 Urine
9.3 Blood
9.4 Other Sample Types
  9.4.1 Saliva
  9.4.2 Cerebrospinal fluid
  9.4.3 Plasma

10 GLOBAL LIQUID BIOPSY MARKET, BY END USER

10.1 Introduction
10.2 Academic and Research Centers
10.3 Hospitals and Physician Laboratories
10.4 Diagnostic centres & Reference Laboratories

11 GLOBAL SMART LOCK MARKET, BY GEOGRAPHY

11.1 Introduction
11.2 North America
  11.2.1 US
  11.2.2 Canada
  11.2.3 Mexico
11.3 Europe
  11.3.1 Germany
  11.3.2 UK
  11.3.3 Italy
  11.3.4 France
  11.3.5 Spain
  11.3.6 Rest of Europe
11.4 Asia Pacific
  11.4.1 Japan
  11.4.2 China
  11.4.3 India
  11.4.4 Australia
  11.4.5 New Zealand
  11.4.6 South Korea
  11.4.7 Rest of South America
11.5 South America
  11.5.1 Argentina
  11.5.2 Brazil
  11.5.3 Chile
  11.5.4 Rest of South America
11.6 Middle East & Africa
  11.6.1 Saudi Arabia
  11.6.2 UAE
  11.6.3 Qatar
  11.6.4 South Africa
  11.6.5 Rest of Middle East & Africa

12 KEY DEVELOPMENTS

12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies

13 COMPANY PROFILING

13.1 Roche Diagnostics
13.2 Guardant Health, Inc
13.3 Illumina, Inc
13.4 Biocept, Inc.
13.5 Myriad Genetics, Inc
13.6 Qiagen N.V.
13.7 Genomic Health, Inc
13.8 Thermo Fisher Scientific Inc
13.9 Bio-Rad Laboratories, Inc
13.10 Epic Sciences
13.11 Exosome
13.12 Cynvenio
13.13 Guardant Health
13.14 Personal Genome Diagnostics
13.15 Janssen Diagnostics, LLC.

List Of Tables

LIST OF TABLES

Table 1 Global Liquid Biopsy Market Outlook, By Region (2014-2023) (US $MN)
Table 2 Global Liquid Biopsy Market Outlook, By Clinical Application (2014-2023) (US $MN)
Table 3 Global Liquid Biopsy Market Outlook, By Treatment Monitoring (2014-2023) (US $MN)
Table 4 Global Liquid Biopsy Market Outlook, By Recurrence Monitoring (2014-2023) (US $MN)
Table 5 Global Liquid Biopsy Market Outlook, By Early Cancer Screening (2014-2023) (US $MN)
Table 6 Global Liquid Biopsy Market Outlook, By Therapy Selection (2014-2023) (US $MN)
Table 7 Global Liquid Biopsy Market Outlook, By Products & Services (2014-2023) (US $MN)
Table 8 Global Liquid Biopsy Market Outlook, By Platforms & Instruments (2014-2023) (US $MN)
Table 9 Global Liquid Biopsy Market Outlook, By Assay Kits & Reagents (2014-2023) (US $MN)
Table 10 Global Liquid Biopsy Market Outlook, By Services (2014-2023) (US $MN)
Table 11 Global Liquid Biopsy Market Outlook, By Cancer Type (2014-2023) (US $MN)
Table 12 Global Liquid Biopsy Market Outlook, By Breast Cancer (2014-2023) (US $MN)
Table 13 Global Liquid Biopsy Market Outlook, By Liver Cancer (2014-2023) (US $MN)
Table 14 Global Liquid Biopsy Market Outlook, By Lung Cancer (2014-2023) (US $MN)
Table 15 Global Liquid Biopsy Market Outlook, By Colorectal Cancer (2014-2023) (US $MN)
Table 16 Global Liquid Biopsy Market Outlook, By Prostate Cancer (2014-2023) (US $MN)
Table 17 Global Liquid Biopsy Market Outlook, By Other Cancer Types (2014-2023) (US $MN)
Table 18 Global Liquid Biopsy Market Outlook, By Circulating Biomarker (2014-2023) (US $MN)
Table 19 Global Liquid Biopsy Market Outlook, By Circulating Tumor DNA (CTDNA) (2014-2023) (US $MN)
Table 20 Global Liquid Biopsy Market Outlook, By Extracellular Vesicles (Evs) (2014-2023) (US $MN)
Table 21 Global Liquid Biopsy Market Outlook, By Circulating Tumor Cells (2014-2023) (US $MN)
Table 22 Global Liquid Biopsy Market Outlook, By Cell-Free DNA (2014-2023) (US $MN)
Table 23 Global Liquid Biopsy Market Outlook, By Exosomes (2014-2023) (US $MN)
Table 24 Global Liquid Biopsy Market Outlook, By Other Circulating Biomarkers (2014-2023) (US $MN)
Table 25 Global Liquid Biopsy Market Outlook, By Sample Type (2014-2023) (US $MN)
Table 26 Global Liquid Biopsy Market Outlook, By Urine (2014-2023) (US $MN)
Table 27 Global Liquid Biopsy Market Outlook, By Blood (2014-2023) (US $MN)
Table 28 Global Liquid Biopsy Market Outlook, By Other Sample Types (2014-2023) (US $MN)
Table 29 Global Liquid Biopsy Market Outlook, By Saliva (2014-2023) (US $MN)
Table 30 Global Liquid Biopsy Market Outlook, By Cerebrospinal fluid (2014-2023) (US $MN)
Table 31 Global Liquid Biopsy Market Outlook, By Plasma (2014-2023) (US $MN)
Table 32 Global Liquid Biopsy Market Outlook, By End User (2014-2023) (US $MN)
Table 33 Global Liquid Biopsy Market Outlook, By Academic and Research Centers (2014-2023) (US $MN)
Table 34 Global Liquid Biopsy Market Outlook, By Hospitals and Physician Laboratories (2014-2023) (US $MN)
Table 35 Global Liquid Biopsy Market Outlook, By Diagnostic centres & Reference Laboratories (2014-2023) (US $MN)
NOTE: Tables for North America, Europe, South America, South America and Middle East & Africa are represented in the same manner above.